The European Medicines Agency
(EMA) has released for consultation
a document relating to productspecific
guidance on bioequivalence
studies for four active substances
- asenapine, prasugrel, sitagliptin
and zonisamide.
EMA says it’s decided to
routinely publish product-specific
bioequivalence guidance to provide
a more consistent apporach to
the assessment of marketing
authorisation applications for
generic medicines in the EU.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 15
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.